News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC Fails to Win FDA Approval for Axanum
June 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- AstraZeneca Plc, the U.K.’s second- largest drugmaker, failed to get approval from U.S. regulators for an experimental treatment to prevent ulcers.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
AstraZeneca
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Cancer
Replimune gets early August decision date for twice-rejected melanoma drug
June 26, 2026
·
3 min read
·
Tristan Manalac
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
·
3 min read
·
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Approvals
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
June 25, 2026
·
2 min read
·
Tristan Manalac